About 600 results
Open links in new tab
  1. Pioneering AI Drug Discovery | Recursion

    Our data and the Recursion OS enable us to train intelligent machine learning models for AI drug discovery and development, which help us rapidly identify new targets and design highly …

  2. Recursion's Drug Discovery Pipeline | Recursion

    Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of potential best-in-class and first-in-class therapeutic assets. We focus on indications with high …

  3. Careers at Recursion: Join Our Mission | Recursion

    Embark on a career journey with Recursion. Dive into opportunities, culture, and the impact you can make. Apply to work with us today!

  4. Our Unique Approach to AI Drug Discovery | Recursion

    Unlike traditional drug discovery, which begins with a specific target or hypothesis, we leverage the Recursion OS — our drug discovery and development platform for AI in pharma connects …

  5. Meet our Team | Recursion

    Get acquainted with the brilliant minds behind Recursion. Dive into our team's passion, expertise, and vision. Read more about our team today!

  6. Recursion Pharmaceuticals, Inc. - Recursion to Report Third …

    Oct 28, 2025 · Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New …

  7. Our TechBio Mindset | Recursion

    The recursion mindset is the deep belief and commitment to industrializing drug discovery through automation, algorithms, and data to deliver on our mission. This is made manifest through our …

  8. AI-Driven Drug Discovery Insights | Recursion

    Oct 29, 2025 · Explore Recursion's latest blog posts on AI, automation, and molecular modeling in drug discovery. Stay informed with cutting-edge insights!

  9. Recursion Pharmaceuticals, Inc.

    Oct 28, 2025 · Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry …

  10. Recursion Pharmaceuticals, Inc. - Press Releases

    Jun 6, 2025 · Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia